The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

The pharmaceutical company expects the expansion will create thousands of jobs.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...